跳至主要内容
临床试验/NCT00822003
NCT00822003已完成1 期

Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile Following an Oral Glucose Tolerance Test in Healthy Male Subjects

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
16
试验地点
1

研究概览

简要总结

The investigators aimed to investigate the pharmacokinetic and pharmacodynamic effects of a single dose (2 mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT) in 16 healthy males

详细描述

Background: Glucagon like peptide-1 (GLP-1) promotes satiety and reduces food intake. GLP-1 is secreted from intestinal L-cells into the splanchnic circulation, it is (i) subject to rapid breakdown and (ii) submitted to a high liver extraction. Highest concentrations of GLP-1 are therefore found in the splanchnic blood rather than in the systemic circulation. An oral delivery system would mimick the physiological path of endogenous secretion. Objective: We aimed to investigate the pharmacokinetic and pharmacodynamic effects of a single dose (2 mg) of oral GLP-1 administered prior to an oral glucose tolerance test (oGTT) in 16 healthy males.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • healthy male subjects
  • no gastrointestinal or endocrine disorder

排除标准

  • alcohol or drug abuse
  • active virus hepatitis

研究组 & 干预措施

1

Active Comparator

Human GLP-1

干预措施: Oral GLP-1 (Drug)

2

Placebo Comparator

Placebo tablet

干预措施: Placebo (Drug)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other

研究点 (1)

Loading locations...

相似试验